Uttarakhand Suspends Permissions Of 14 Products Of Ramdev’s Pharma Firms

Haridwar: An Indian state regulator has suspended manufacturing licences of 14 products made by pharmaceutical companies of the country’s most popular yoga guru for repeatedly publishing misleading advertisements about their efficacy, a government order showed.

The order is the latest setback for Baba Ramdev whose TV shows, yoga cures and traditional medicine offerings for diseases have made him popular in India and other nations.

The Supreme Court of India has in recent weeks repeatedly criticised Ramdev for not complying with its directives in an ongoing lawsuit to stop misleading advertisements of some of his traditional ayurvedic medicines.

The manufacturing permits of Ramdev’s companies were suspended in an April 15 order by the drug regulator of traditional medicines in northern Uttarakhand state. Reuters is the first to report the order which is not public.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

The list of 14 products whose licences were suspended included Ramdev’s traditional medicines for asthma, bronchitis and diabetes.

The manufacturing permits are “suspended with immediate effect”, Mithilesh Kumar of the state regulator wrote in his order.

A spokesperson for Ramdev said he did not have any immediate comment on the matter.

Related Posts

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) has notified retail price of 42 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including anti hypertensive,…

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

New Delhi– In a landmark development for global child health, the World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first and only antimalarial medicine specifically developed…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

Laughing all the Way to Health with Sir Ganga Ram Hospital

Laughing all the Way to Health with Sir Ganga Ram Hospital

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop